Practice Nurses Report Surge in Patient Inquiries About Weight Loss Medications
London, UK – Practice nurses in England are experiencing a significant increase in patient interactions related to weight loss medications, notably tirzepatide, following guidance issued to commissioners on June 23rd to roll out the drug in primary care. A recent survey conducted by Nursing in Practice reveals a ample rise in patient questions and discussions surrounding these treatments.
The survey, open from July 2nd to July 21st, 2025, and completed by 480 respondents in England, aimed to gauge the impact of wider access to weight loss drugs. It found a notable number of interactions now involve tirzepatide, either as the primary concern or as a related topic during routine appointments.
Experts emphasize that weight loss drugs should be considered “an option within a suite of different treatments,” particularly in diabetes care, and as “part of this toolkit” alongside lifestyle interventions like exercise classes and diet management. Mr. Metcalfe-O’Shea highlighted the importance of nurses being aware of locally available services to support patients outside of medicinal routes.
Recent guidance from the National Institute for Health and Care Excellence (NICE) underscores the need for improved support for patients after weight loss treatment to help maintain healthy weight. Together, the Medicines and healthcare products Regulatory Agency (MHRA) has cautioned women using weight loss medications – including those for diabetes – to utilize “effective contraception,” as these drugs should not be used during pregnancy, while trying to conceive, or during breastfeeding.
The increase in patient interest comes amid reports of judgement faced by those with diabetes,according to a recent charity finding. Nurses are therefore positioned to play a crucial role in supporting patients navigating these new treatment options and addressing associated health considerations.
